



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 6413**  
Noboru TSUCHIMORI et al. : Attorney Docket No. 2007\_0561  
Serial No. 10/511,112 : Group Art Unit 1617  
Filed October 21, 2004 : Examiner S. Kantamneni  
USE OF COMPOUNDS  
HAVING CCR ANTAGONISM : **Mail Stop: AMENDMENT**

---

**RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is responsive to the Official Action dated August 27, 2007, the time for responding thereto being extended for two months in accordance with a Petition for Extension submitted concurrently herewith.

The Official Action constitutes a requirement for restriction.

Applicants select to prosecution the invention of Group I, with traverse.

Group I is directed to claims 1-4 and 9-10. The Action states that they are drawn to a method for the prevention or treatment of a graft-versus host disease and/or rejection reactions comprising administering a compound having a CCR antagonistic effect represented by the formula (I), formula (II), formula (III), formula (IV), or formula (eI).

However, Applicants wish to point out that the claims of this group, particularly claim 2, include a method for the prevention or treatment of chronic rheumatoid arthritis, autoimmune diseases, allergic disorders, ischemic brain cell damage, myocardial infarction, chronic nephritis, and arteriosclerosis. It is respectfully submitted that these methods recited in claim 2 should be